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Mastocytosis is a disorder resulting from an abnormal mast cell (MC) accumulation in tis-
sues that is often associated with the D816V mutation in KIT, the tyrosine kinase receptor 
for stem cell factor. Therapies available to treat aggressive presentations of mastocytosis 
are limited, thus exploration of novel pharmacological targets that reduce MC burden is 
desirable. Since increased generation of the lipid mediator sphingosine-1-phosphate 
(S1P) by sphingosine kinase (SPHK) has been linked to oncogenesis, we studied the 
involvement of the two SPHK isoforms (SPHK1 and SPHK2) in the regulation of neo-
plastic human MC growth. While SPHK2 inhibition prevented entry into the cell cycle in 
normal and neoplastic human MCs with minimal effect on cell survival, SPHK1 inhibition 
caused cell cycle arrest in G2/M and apoptosis, particularly in D816V-KIT MCs. This 
was mediated via activation of the DNA damage response (DDR) cascade, including 
phosphorylation of the checkpoint kinase 2 (CHK2), CHK2-mediated M-phase inducer 
phosphatase 3 depletion, and p53 activation. Combination treatment of SPHK inhibitors 
with KIT inhibitors showed greater growth inhibition of D816V-KIT MCs than either inhib-
itor alone. Furthermore, inhibition of SPHK isoforms reduced the number of malignant 
bone marrow MCs from patients with mastocytosis and the growth of D816V-KIT MCs in 
a xenograft mouse model. Our results reveal a role for SPHK isoforms in the regulation of 
growth and survival in normal and neoplastic MCs and suggest a regulatory function for 
SPHK1 in the DDR in MCs with KIT mutations. The findings also suggest that targeting 
the SPHK/S1P axis may provide an alternative to tyrosine kinase inhibitors, alone or 
in combination, for the treatment of aggressive mastocytosis and other hematological 
malignancies associated with the D816V-KIT mutation.
Keywords: sphingosine kinase, sphingosine kinase inhibitor, sphingosine-1-phosphate, mastocytosis, D816V, KiT, 
mast cells
Abbreviations: ATM, ataxia telangiectasia mutated; ATR, ataxia telangiectasia and Rad3-related protein; BAX, BCL-2-
associated X protein; BCL2, B-cell lymphoma 2; BMMCs, bone marrow-derived mast cells; CASP2, caspase 2; CASP3, caspase 
3; CDC25c, M-phase inducer phosphatase 3; CDK1, cyclin-dependent kinase 1; CHK, checkpoint kinase; DDR, DNA damage 
response; GADD45α, growth arrest and DNA-damage-inducible protein alpha; H2AX, H2A histone family member X; HuMC, 
human mast cell; IPA, ingenuity pathway analysis; KIT, stem cell factor receptor; MC, mast cell; p53, tumor protein p53; SM, 
systemic mastocytosis; S1P, sphingosine-1-phosphate; SPHK, sphingosine kinase; SPHK1-I, sphingosine kinase 1 inhibitor 
SKI-178; SPHK2-I, sphingosine kinase 2 inhibitor ABC294640.
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inTrODUcTiOn
Sphingosine-1-phosphate (S1P) is a lipid mediator with multiple 
biological functions. Evidence indicates that S1P plays a signifi-
cant role in cancer as it promotes cell migration and cell prolifera-
tion, prevents cell death, and induces angiogenesis (1, 2). S1P is 
generated in cells in response to growth factors, cytokines, and 
other extracellular stimuli through the activation of two isoforms 
of sphingosine kinase (SPHK1 and SPHK2) (3–5). Upregulated 
expression of SPHK, particularly SPHK1, and increased levels of 
S1P have been linked with poor cancer prognosis and resistance 
to cytotoxic therapy agents in malignant cells from solid tumors, 
lymphomas, and leukemias (1, 6–8). Selective targeting of either 
SPHK1 or SPHK2 can effectively inhibit malignant cell growth 
in culture and in xenograft models and the preferential effect 
of one isoform over the other appears to be cell type specific (1, 
9–15). Nevertheless, an inhibitor of SPHK2, ABC294640, is in 
early clinical trials for patients with pancreatic cancer and dif-
fuse large B  cell lymphomas (clinical trials NCT01488513 and 
NCT02229981) (16). In addition, safingol, which inhibits SPHK1 
and SPHK2, has been used in combination with cisplatin in Phase 
I clinical trials (clinical trial NCT00084812) for the treatment of 
locally advanced or metastatic solid tumors (17).
Abnormal mast cell (MC) proliferation and accumulation in 
various tissues occurs in mastocytosis, which in its more aggressive 
forms can be life-threatening (18, 19). This increased MC burden 
in systemic mastocytosis (SM) is most often associated with the 
presence of an activating mutation in the catalytic domain of KIT, 
the receptor for stem cell factor, that causes ligand-independent 
activation of KIT and downstream signaling, especially within the 
MC compartment (20–22). Thus, targeting KIT activity has been 
a focus of pharmacological strategies to treat aggressive SM, with 
the limitation that the extended tyrosine kinase conformation of 
D816V-KIT is not inhibited by tyrosine kinase inhibitors such 
as imatinib (21, 23). In addition, midostaurin (PKC412), which 
effectively blocks D816V-KIT activity (24) and the growth of MC 
expressing D816V-KIT (25), has time-limited effects on improve-
ment of clinically relevant responses in patients with aggressive 
SM (26). Thus, new strategies that target critical growth signaling 
pathways in neoplastic MCs are needed.
Mast cells of murine or human origin express both SPHK1 
and SPHK2 isoforms, which are activated following IgE receptor 
stimulation, and S1P consequently generated plays a critical role 
in IgE-mediated release of mediators and cytokines (27–31). 
In addition, receptors that are important for maturation/growth/
survival of MCs such as KIT and the IL-3 receptor also stimulate 
SPHKs (27). However, it has not been studied whether SPHK and 
S1P regulate MC growth and survival.
Here, we show that SPHK1 and SPHK2 are upregulated in 
neoplastic human MCs and are important regulators of their 
proliferation and survival in culture. Inhibition of SPHK2 reduces 
the growth of primary mouse and human mast cells (HuMCs) 
cultures and neoplastic human MC lines by slowing their entry 
into the cell cycle. On the other hand, SPHK1 inhibition induces 
cell cycle arrest followed by cell death in neoplastic MCs express-
ing D816V-KIT but not in normal MCs. We demonstrate that 
this effect is mediated by a previously unrecognized regulation 
of the checkpoint kinases CHK1 and CHK2 and the activation of 
the DNA damage response (DDR) cascade. Inhibition of SPHKs 
also reduces the number of malignant MCs from bone marrow of 
mastocytosis patients ex vivo and in a preclinical mouse model of 
tumor xenografts using a MC line with D816V-KIT. Our results 
show promise for clinical investigation of this non-tyrosine 
kinase-based approach to the treatment of aggressive SM and 
other hematological malignancies with D816V-KIT.
MaTerials anD MeThODs
reagents
Reagents were obtained as follows: anti-rabbit IgG 800CW 
and anti-mouse IgG 680 RD from Licor Biosciences (Lincoln, 
NE, USA); goat anti-rabbit IgG-AF488 from Abcam (Cambridge, 
MA, USA); and anti-CD117-BV605, anti-FcεRI-BV421, and 
anti-CD25-BV711 from Biolegend (San Diego, CA, USA). 
Antibodies against phospho-AKT(Ser473), BCL-2-associated 
X protein (BAX), B-cell lymphoma (BCL2), cleaved caspase 2 
(CASP2), caspase 3 (CASP3), cleaved CASP3, M-phase inducer 
phosphatase 3 (CDC25c), cyclin-dependent kinase 1 (CDK1), 
phospho-CHK2(Thr68), phospho-ERK(Thr202/Tyr204), p38, 
phospho-p38(Thr180/Tyr182), and p53 were from Cell Signaling 
Technology (Danvers, MA, USA); anti-CASP2 and anti-CHK2 
were from Millipore (Billerica, MA, USA); anti-CHK1, anti-
phospho-CHK1(Ser345), hIL-6, and hSCF were from R&D 
Systems (Minneapolis, MN, USA); anti-phospho-p53(Ser20) 
(human) and anti-GADD45 were from Santa Cruz (Santa Cruz, 
CA, USA); anti-H2A histone family member X (H2AX) and 
anti-phospho-H2AX (Ser130) were from Abclonal (Woburn, 
MA, USA); anti-SPHK1 was from ECM Biosciences (Versailles, 
KY, USA), anti-SPHK2 was from MyBioSource (San Diego, CA, 
USA); anti-CD34-APC and anti-AKT were from BD Biosciences 
(San Jose, CA, USA); anti-ERK and anti-SPHK2 (used for IHC) 
were from Thermo Fisher Scientific (Waltham, MA, USA); anti 
β-actin and anti-SPHK1 (used for IHC) were from Sigma Aldrich 
(St. Louis, MO, USA); mouse IL-3 and SCF were from Peprotech 
Inc. (Rocky Hill, NJ, USA); the SPHK1 inhibitor SKI-178 was 
from Millipore and the SPHK2 inhibitor ABC294640 was from 
MedKoo Biosciences (Morrisville, NC, USA).
human samples, cell cultures,  
and cell lysates
CD34+ peripheral blood progenitors from human blood and 
bone marrow aspirates from patients with SM were obtained 
following informed consent under protocols approved by the 
NIAID Institutional Review Board (98-I-0027 and 02-I-0277). 
The characteristics of these patients are specified in Table S1 in 
Supplementary Material. Primary HuMC cultures were derived 
from CD34+ progenitors as described (32, 33); and mononuclear 
cells from marrow aspirates were separated in a Ficoll gradient 
and cultured for 5  days in StemPro media supplemented with 
100 ng/mL SCF (34).
HMC-1.1 and HMC-1.2 were kindly provided by Dr. 
Butterfield at the Mayo Clinic. HMC-1 cells, LAD-2 cells, and 
murine bone marrow-derived mast cells (BMMCs) from Sphk1-, 
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Sphk2-deficient, and WT mice were cultured as described 
(28, 35, 36). P815 mastocytoma murine cells with a mutation 
homologous to the human D816V mutation were from ATCC 
(Manassas, VA, USA). HCT116 cells with or without the D816V-
KIT introduced by CRISPR were from Thermo Fisher Scientific. 
P815 and HCT116 cells were cultured as specified by the respec-
tive providers. Cell lysates for Western blots were prepared from 
1 × 106 cells and processed as described (37).
Flow cytometry analysis of Mcs From 
Bone Marrow aspirates
Bone marrow cells cultured for 5 days as described above were 
washed once with PBS, resuspended in 200 µL PBS containing 
aqua live/dead stain (Thermo Fisher Scientific), and incubated 
in the dark for 20 min at room temperature. After washing with 
3% FBS in PBS, cells were incubated with 50 µL of an antibody 
cocktail containing anti-CD117(KIT)-BV605, anti-FcεRI-BV421, 
anti-CD34 -APC, and anti-CD25-BV711 for 30 min at room tem-
perature. Cells were then washed once, resuspended in 200 µL 
PBS, and analyzed by flow cytometry. Cells were gated based on 
forward/side scatter, single cells, and live cells. CD34−/CD25+ 
cells co-expressing CD117(KIT) and FcεRI were analyzed.
Determination of cell growth
2.5 × 106 LAD2 or murine BMMC were plated in T25 flasks at 
0.5 × 106 or 1 × 106/mL, respectively, and 4 × 106 HCT116 cells 
at 0.5  ×  106/mL. Cells were incubated with or without inhibi-
tors at the indicated concentrations for 3  days or as indicated. 
For BMMCs, culture medium was changed after 7  days, and 
cell concentration was adjusted. Viable cells excluding trypan 
blue were then counted. Alternatively, 5 × 104 HMC-1 or P815 
cells were plated in 96-well plates at 0.5 × 106 cells/mL with or 
without inhibitors. At the indicated times, an equal volume of 
2× CyQuant®Direct detection reagent containing a green fluores-
cent nucleic acid stain for viable cells (Thermo Fisher Scientific) 
was added to the wells. After 1 h at 37°C, fluorescence was meas-
ured at 480/535 nm.
cell cycle analysis
LAD2 or HMC-1 cells (1 × 106) were plated at 0.5 × 106 cells/mL 
in 6-well plates and cultured with the SPHK inhibitors or vehicle 
for 3 days. Cells were then harvested and fixed in 70% ethanol 
at 4°C for 2 h. After washing twice with PBS, cells were stained 
with PI/RNase Staining Buffer (BD Pharmingen) and analyzed 
on a LSR II (BD Biosciences) flow cytometer for PI positive 
signal (Emission at 605 nm). Single cells were gated and PI signal 
visualized using histogram plots. Distribution of cells containing 
DNA characteristic G0-G1, S, and G2/M cell cycle phases was 
determined using FlowJo as described (38).
cell Death/apoptosis analysis
The annexin V FITC Apoptosis Detection Kit II (BD Pharmingen) 
was used following the manufacturer’s protocol. Cells 
(1  ×  106  cells/mL) were incubated with vehicle or the SPHK 
inhibitors for 3  days and stained with FITC-annexin V for 
30 min in the dark on ice. After washing, 7-amino-actinomycin 
D (7-AAD), which binds DNA with high affinity but is excluded 
by intact cells, was added to differentiate early apoptosis from late 
apoptosis or other forms of cell death, and cells were analyzed by 
flow cytometry (LSR II BD). The percentage of early apoptotic 
cells was determined as the frequency of annexin V positive/7-
AAD negative cells, while the percentage of all dead cells was 
determined as the frequency of the 7-AAD positive population 
(annexin V positive and negative).
expression of cell cycle genes  
by Quantitative Pcr arrays
Total RNA was isolated from HMC-1.2 cells (3  ×  106) treated 
with vehicle or SPHK inhibitors for 24  h. RNA was converted 
into cDNA using the RT2 First-Strand Kit (Qiagen), and then 
used as a template to perform a quantitative RT2 Profiler PCR 
Array for Human Cell Cycle (Qiagen PAHS-020Z) to analyze the 
expression levels of 84 genes involved in regulation of cell cycle. 
The raw threshold cycle data were analyzed using SA Biosciences 
web-based tool,1 as instructed by the manufacturer. An ingenuity 
pathway analysis (IPA) program (Mountain View, CA, USA) was 
employed for pathway analysis using the fold changes between 
the SPHK1-I- or SPHK2-I-treated cells compared with vehicle-
treated cells. Changes in expression of cyclin genes were con-
firmed by using specific TaqMan gene expression assays (Thermo 
Fisher Scientific).
immunocytochemistry
Human mast cells, LAD2, HMC-1.1, and HMC-1.2 cells 
(2  ×  105  cells/200  μL) were plated for 20  min in LabTek II 
Chamber Slides (LabTek, Rochester, NY, USA) coated with 
polylysine 0.01% (Sigma-Aldrich). Cells were fixed with 4% PFA 
(Affimetrix, Cleveland, OH, USA) for 20 min at 4°C and permea-
bilized with PBS + 0.2% TritonX-100 for 30 min. After blocking 
with PBS + 1% BSA + Fc blocking antibody (1:50) (eBioscience), 
cells were incubated with anti-SPHK1 or anti-SPHK2 for 1 h at 
4°C with agitation and proteins detected with AF488-labeled 
secondary antibody. DAPI was used for nuclear staining in com-
bination with Prolong Gold Antifade Mountant (Thermo Fisher 
Scientific). Images were captured with a Leica DMI 8 confocal 
microscope and analyzed with Imaris software.
sphingolipid analysis
Lipids were extracted from 8  ×  106 HMC-1.2 cells following 
treatment with SPHK1-I (10 µM) or SPHK2-I (50 µM) for 16 h. 
Ceramides, sphingosine, and S1P were measured by HPLC-
tandem MS by the Lipidomics Core at the Medical University of 
South Carolina on a Thermo Finnigan (Waltham, MA, USA) TSQ 
7000 triple quadrupole mass spectrometer, operating in a multiple 
reaction-monitoring positive ionization mode as described (39). 
The sphingolipid concentration was normalized using inorganic 
phosphate measurements of the lipid extracts.
Mice and Xenograft Model
All studies involving mice were performed in accordance with 
NIH guidelines and with the animal study proposal (LAD2E) 
1 www.sabiosciences.com/pcrarraydataanalysis.
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approved by the NIH/NIAID Animal Care and Use Committee. 
WT, Sphk1-, and Sphk2-null mice were generated as described 
(40), and bred within NIAID animal facilities.
For the xenograft tumor model, NSG mice (NOD-scid 
IL2R γnull) from Jackson laboratories (Bar Harbor, ME, USA) 
(6–8 weeks) were injected subcutaneously with 1 × 106 HMC-1.2 
neoplastic MCs. Cells were washed and injected in 100 µL of RPMI 
medium into the right flank. Tumor size was measured with a 
Mitutoyo IP65 caliper. Tumor volume was calculated following 
the solid tumor formula: volume (mm3) =  (length × width2)/2 
(41). Once the tumors reached 50 mm3 (within 18–23 days), mice 
were injected i.p. daily for a maximum of 15 days with SPHK1-I 
or SPHK2-I at 20 or 40 mg/kg, as indicated, or vehicle (PEG400 
with 5% DMSO) and the tumor size was measured after each 
injection. Mice were euthanized when tumors reached 1.5 cm in 
one dimension (days 11–15).
statistical analysis
Statistical significance was determined using Student’s t-test. 
Comparison of changes over time between different groups 
was performed using two-way ANOVA using Prism software. 
A p value of less than 0.05 was considered significant. Data are 
shown as mean ± SEM unless specified otherwise.
resUlTs
sPhKs regulate the growth of normal 
Murine and human Mcs
To investigate the role of SPHKs on MC proliferation, we first 
compared the growth rates of MCs derived from Sphk1- and 
Sphk2-deficient bone marrow progenitors (BMMC) to normal 
BMMCs. As shown in Figure 1A, growth rates of Sphk-deficient 
cells were significantly reduced compared with WT BMMCs. 
Treatment WT-BMMCs with small molecule inhibitors specific 
for SPHK1 [SKI-178 (42); referred here as SPHK1-I] or SPHK2 
[ABC294640 (12, 43); referred in here as SPHK2-I] exhibited 
similar effects on growth rates as BMMCs genetically deficient 
in Sphk1 or Sphk2 (Figure 1B). We then explored the effect of 
these inhibitors on the proliferation/survival of 6-week cultures 
of CD34+-derived HuMCs containing more than 85% KIT+/
FcεRI+ double-positive MCs. While SPHK1-I did not show any 
significant effect, treatment with SPHK2-I markedly reduced 
HuMC numbers in cultures from three different healthy donors 
(Figure 1C). The data support a role for SPHKs in the growth/
survival of normal human and mouse MCs, although the relative 
involvement of SPHK1 appears to differ between human and 
mouse by mechanisms unrelated to the relative expression of 
SPHK1 since SPHK1 is more abundant in human than in mouse 
MCs (28).
sPhKs are Upregulated in neoplastic Mcs
Enhanced SPHK expression in a number of malignant cell types 
has been associated with increased proliferation, cancer prognosis, 
and clinicopathological parameters of disease (1, 44). Similarly, 
we found an increase in the expression of SPHK1 and SPHK2 
in mastocytosis MC lines (i.e., LAD2 and HMC-1) compared 
with normal HuMCs (Figure  2A; Figure S1 in Supplementary 
Material), which was variable depending on the donor. Of note, 
expression and activity of SPHK2 in normal HuMCs albeit much 
lower than in neoplastic cells were on the average higher than that 
for SPHK1 (28).
Although SPHKs are predominantly cytosolic enzymes (45), 
both SPHK1 and SPHK2 (46, 47) can be abundantly expressed in 
the nucleus of cancer cell lines such as MCF7, COS7, and HeLa 
cells and a higher nuclear expression of SPHK1 has been associ-
ated with significantly shorter survival in breast cancer patients 
(44). Using IHC for SPHK1 and SPHK2, we observed that SPHK1 
and SPHK2 were distributed homogeneously throughout the 
cell in normal HuMCs, and more concentrated in perinuclear 
areas and the plasma membrane (Figure S1 in Supplementary 
Material). Analysis of the confocal IHC images confirmed the 
increased overall cellular expression of SPHKs in neoplastic MCs 
and a higher density of SPHK, particularly SPHK1, in the nucleus 
of neoplastic MCs compared with normal HuMCs (Figure S1 in 
Supplementary Material). This was especially apparent in HMC-
1.2 cells. However, the percentage of nuclear SPHK (respect to the 
total cellular content) was similar among the cell types suggesting 
that the enrichment of nuclear SPHK was the result of higher 
overall expression but not of a differential distribution pattern in 
neoplastic cells.
sPhK1 is critical for the growth/survival 
of cells With D816V-KiT
We then examined whether the growth of neoplastic MCs was 
influenced by SPHK1-I or SPHK2-I as we found in normal MCs. 
While treatment with SPHK2-I resulted in a 40–50% reduction 
in the number of both LAD2 (Figure  2B) and HMC-1 cells 
(Figures  2C,D), the effect of SPHK1-I differed depending on 
the MC line. Similar to normal HuMCs cultures (Figure  1C), 
SPHK1-I had only a modest inhibitory effect in the growth 
of LAD2 MCs (Figure  2B). However, unlike LAD2 cells, the 
growth of HMC-1.1 and HMC-1.2 cells carrying oncogenic 
KIT mutations was markedly reduced by 60% (Figures 2C,D). 
Furthermore, HMC-1.2 MCs, harboring the D816V-KIT muta-
tion in addition to the G560V-KIT present in HMC-1.1, were 
significantly more sensitive to lower concentrations of SPHK1-I 
than HMC-1.1 cells (compare Figures  2C,D). This contrasted 
with the lack of effects of SPHK1-I on the growth of normal 
HuMCs (Figure 1C), although the effects varied slightly in the 
different donors, potentially reflecting, to some extent, differ-
ences in SPHK expression.
Of note, SPHK1 and 2 inhibitors were more effective at reduc-
ing the expansion of HMC-1.2 cells than 300 nM PKC412 or 2 µM 
dasatinib (Figure 2E), which are known to inhibit D816V-KIT. 
Combination treatment with dasatinib or PKC412 and SPHK 
inhibitors showed higher inhibition than either inhibitor alone, 
although the combination with PKC412 was not statistically dif-
ferent compared to SPHK inhibitors alone (Figure 2E).
We also examined whether other cells carrying D816V-KIT 
also had higher sensitivity to SPHK1-I. The growth of the mas-
tocytoma MC line P815 containing the murine equivalent to 
human D816V-KIT was also remarkably inhibited by SPHK1-I 
FigUre 1 | SPHK1 and SPHK2 are critical for the growth and survival of mouse and human MCs. (a) Number of viable bone marrow-derived mast cells (BMMCs) 
from WT, Sphk1-, and SphK2-deficient mice over time in culture. (B) Number of viable WT BMMCs treated with either the SPHK1-specific inhibitor SKI-178 (5 µM) 
(SPHK1-I) or the SPHK2-specific inhibitor ABC294640 (50 µM) (SPHK2-I). 0.5 × 106 cells were plated and cultured for 14 days and viable cells excluding trypan blue 
counted at the indicated times. Values are mean ± SEM of data from three independent cultures. (c) Effect of SPHK-I in the growth of 5- to 6-week-old CD34+-
derived human mast cells (HuMCs). Cultures derived from three independent healthy donors were incubated with SPHK1-I (10 µM), SPHK2-I (50 µM), or vehicle 
(0.1% DMSO) for 5 days and viable cells excluding trypan blue counted. Data are shown as mean ± SEM of triplicate wells and are representative of three 
independent experiments. Significant differences from untreated and treated pairs are shown thus; *p < 0.05, **p < 0.01, ***p < 0.001.
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compared with normal BMMC (Figure S2A in Supplementary 
Material). Furthermore, the colon cancer epithelial cell line 
HCT116 was susceptible, as most cancer cells are, to growth 
inhibition by either SPHK1-I or SPHK2-I, but they were even 
more susceptible earlier on to the effects of the SPHK1-I when a 
mutation in D816V-KIT was additionally introduced (Figure S2B 
in Supplementary Material). The finding of a higher susceptibility 
of cells carrying D816V-KIT to SPHK1-I is of interest given that 
patients with these mutations are less responsive to KIT inhibitor 
treatments.
Differential effects of sPhK1 and sPhK2 
inhibition on cell cycle arrest and survival 
of neoplastic Mcs
We next explored how SPHK1-I and SPHK2-I affected cell 
growth of neoplastic MCs, focusing on HMC-1.2 since these cells 
have the D816V mutation commonly found in SM. In HMC-1.2, 
inhibition of SPHK1 caused a prominent cell cycle arrest in G2/M 
(Figure 3A) accompanied by extensive apoptosis evidenced by 
annexin V+ staining (Figure 3B), while in contrast inhibition of 
SPHK2 resulted in the accumulation of cells in the G0/G1 phases 
and reduction of the percentage of cells in the S phase (Figure 3A) 
with no major effects on cell death (Figure 3B). G2/M arrest and 
apoptosis induced by SPHK1-I were significantly more promi-
nent in HMC-1.2 than in HMC-1.1 and LAD2 cells (Figure 3C), 
in agreement with their overall effects on cell numbers. SPHK2-I, 
however, prevented the exit from G1 into the S phase in a com-
parable manner in all neoplastic MCs (Figure  3D), consistent 
with its similar effects reducing cell numbers in all the cell lines. 
Treatment of HMC-1.2 with either of these inhibitors did not 
significantly affect the expression of SPHK1 or SPHK2 (data not 
shown).
Subsequent studies on the mechanisms by which these 
inhibitors regulate growth and survival were mostly performed 
in neoplastic MCs with D816V-KIT, i.e., HMC-1.2, because of 
the clinical relevance of this mutation and its resistance to most 
tyrosine kinase inhibitors.
effect of sPhK1 and sPhK2 inhibitors  
on sphingolipid Metabolites
As expected, inhibition of SPHK1 or SPHK2 caused substantial 
reductions in the cellular concentration of S1P, the product of 
FigUre 2 | Enhanced expression of SPHK1 and SPHK2 in neoplastic human MCs and their effect on cell growth. (a) Representative Western blots from one of 
three independent experiments showing immune-reactive bands for SPHK1 (46 kDa) and SPHK2 (70 kDa) in human mast cells (HuMCs) derived from five 
different donors (upper and lower sets of blots) and the neoplastic MC lines LAD2, HMC-1.1, and HMC-1.2. Lysates were prepared from 1 × 106 cells and equal 
protein loading obtained by adjusting to total AKT or β-actin levels. Donor 2 in Figure 1c corresponds to donor #2 in the lower set of blots. (B) Effect of 
SPHK1-I (5 µM) and SPHK2-I (50 µM) in the growth of LAD2 cells. Cells excluding trypan blue were counted 3–7 days after treatment with the inhibitors or 
vehicle. The values represent the percentage of viable cells respect to the number of vehicle-treated viable cells after 3 days in culture (first column). Data are 
represented as mean ± SEM of three independent experiments. Effect of the indicated concentrations of SPHK1-I and SPHK2-I in the growth HMC-1.1 (c) and 
HMC-1.2 (D) for 3 days. (e) Effect of SPHK inhibitors alone or in combination with KIT inhibitors on the growth of HMC-1.2 cells. SPHK1-I (5 µM) or SPHK2-I 
(50 µM) were added to cultures at day 0 alone or together with 300 nM midostaurin (PKC412) or 1 µM Dasatinib for 3 days. In panels (c–e), Cyquant cell 
proliferation assay was used to assess growth inhibition, and data are represented as mean ± SEM of three independent experiments each performed in 
triplicate. The number of cells at the end of the experiment in untreated controls was considered 100%. Horizontal dotted lines represent the number of cells 
originally plated (as a percentage of the cell count at day 3 in untreated cultures). Significant differences from untreated and treated pairs are shown thus; 
*p < 0.05, **p < 0.01, ***p < 0.001.
6
Bandara et al. SPHKs and Neoplastic MC Growth
Frontiers in Immunology | www.frontiersin.org March 2018 | Volume 9 | Article 631
FigUre 3 | Effect of SPHK1 or SPHK2 inhibition on cell cycle arrest and cell death in human neoplastic mast cells. (a) Cell cycle analysis distribution of PI-stained 
HMC-1.2 cells treated with SPHK1-I (5 µM), SPHK2-I (50 µM), or vehicle (0.1% DMSO) for 3 days. After 3 days of treatment, cells were stained with propidium iodide 
(PI) and analyzed by flow cytometry. Percentage of cells in the various phases of the cell cycle is represented in histogram form. A representative cell cycle distribution 
by FACS analysis is also shown. (B) Inhibition of SPHK1 causes cell death in HMC-1.2 cells. HMC-1.2 treated with SPHK inhibitors as in panel (a) were stained with 
7-AAD and annexin V. Annexin V+/7−AAD− cells were considered as cells in early apoptosis (hatched bars) while annexin V+/7-AAD+ cells (black bars) were considered 
as cells in late apoptosis or other possible types of cell death. Cells that stained only for 7-AAD were in a negligible proportion. Comparison of the effects of SPHK1-I 
(c) and SPHK2-I (D) in cell cycle distribution and apoptosis in the different neoplastic MC lines. Cell cycle distribution was determined as in panel (a) and cell death 
as in panel (B), except that the numbers denote the combined percentage of annexin V+/7−AAD− and annexin V+/7−AAD+. In panels (a–D), the values are the 
mean ± SEM of three separate experiments. Significant differences from untreated and treated pairs are shown thus; *p < 0.05, **p < 0.01, ***p < 0.001.
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these lipid enzymes (Figure  4A). The reduction in S1P was 
particularly notable with SPHK2-I treatment (Figure  4A) 
and was accompanied by some accumulation of the substrate, 
sphingosine (Figure  4B). Since sphingosine can be converted 
into ceramide and, in contrast to S1P, ceramide is a sphin-
golipid metabolite that mediates pro-apoptotic and anti-growth 
effects (7, 48), we thus examined whether cell death induced 
by SPHK1-I could be related to increases in ceramide levels. 
However, increases in ceramides at the indicated times were only 
significantly detected in cells treated with SPHK2-I (Figure 4C) 
and therefore, the distinct apoptosis induced by SPHK1-I does 
not seem to implicate ceramide production. Thus, both inhibi-
tors reduced S1P levels in these cells but only SPHK2-I resulted 
in detectable increases in ceramides that could contribute to 
SPHK2-I-mediated growth inhibition, albeit not substantially 
to apoptosis.
sPhK1-i and sPhK2-i Differentially affect 
the expression of genes regulating  
the DDr and repair Pathways
To gain insights into the mechanisms of growth inhibition 
and induction of apoptosis in HMC-1.2 cells by SPHK1-I, we 
investigated the effects of these inhibitors on the expression of 
84 genes that are critical for cell cycle regulation using a qPCR 
array. The original datasets with the changes in gene expression 
induced by SPHK1 or SPHK2 inhibitors can be found in NCBI’s 
Gene Expression Omnibus (49) and are accessible through 
FigUre 5 | Effects of SPHK1 and SPHK2 inhibition in the expression of cell cycle genes. (a) Relative changes in the mRNA levels of the indicated cyclins in 
HMC-1.2 after 24 h treatment with 5 µM SPHK1-I or 50 µM SPHK2-I. Changes in the expression of cyclins were initially determined using a RT2 Profiler PCR Array 
and confirmed by Taqman gene expression assays. (B) Heat map of the canonical pathways affected by the treatment of HMC-1.2 with 5 µM SPHK1-I or 50 µM 
SPHK2-I for 24 h. Changes in expression of 84 genes involved in the cell cycle induced by SPHK1-I or SPHK2-I treatment were determined using a RT2 Profiler PCR 
Array. Fold changes in the genes induced by either inhibitor were then analyzed using the ingenuity pathway analysis (IPA) with 1.5-fold as a cutoff. Shown is a 
comparison analysis done by IPA of the canonical pathways most significantly affected by either inhibitor and sorted by the activation Z score (blue: predicted 
inhibited and red: predicted activated). In bold, pathways related to DNA damage response cascade.
FigUre 4 | Effects of SPHK1 and SPHK2 inhibition in the intracellular levels of sphingolipid metabolites. HMC-1.2 cells were cultured in the presence of SPHK1-I 
(5 µM), SPHK2-I (50 µM), or vehicle (0.1% DMSO) overnight. Cellular lipids were extracted and the cellular amounts of sphingosine-1-phosphate (S1P) (a), 
sphingosine (Sph) (B), and ceramide (c) determined by mass spectrometry. The amount of all the saturated (C14, C16, C18, C20, C22, and C26) and unsaturated 
(C18:1, C20:1, C20:4, C22:1, C24:1, and C26:1) ceramides were combined for simplicity. The total content of phospholipid per sample was used to normalize the 
results. The most abundant ceramide species were C24 and C24:1. The data are presented as mean ± SD of two separate experiments each performed in 
duplicates. Significant differences from untreated and treated pairs are shown thus; *p < 0.05, **p < 0.01. ND indicates “not detected.”
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GEO Series accession number GSE111060.2 Treatment of 
HMC-1.2 cells with either SPHK1-I or SPHK2-I reduced cyclin 
E (CCNE1) mRNA expression, a cyclin responsible for late G1 or 
G1/S transition. Expression of cyclins A and B, which facilitate 
progression into the S and G2 phases (50), was also reduced 
by the inhibitors although more significantly so by SPHK2-I 
(Figure 5A). Analysis of the expression of all cell cycle-related 
genes in the array with the IPA software predicted a downregula-
tion of “S phase entry” and increased “G1/S and G2/M checkpoint 
regulation” as Canonical Pathways regulated by both SPHK1-I 
and SPHK2-I (Figure 5B; Table S2 in Supplementary Material). 
Surprisingly, these results suggest that both inhibitors similarly 
2 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111060 (Accessed: 
February 23, 2019).
restrict progression into S phase and imply that the accumula-
tion in G2/M observed only after SPHK1-I treatment occurs 
by mechanisms other than a specific downregulation of cyclins 
regulating transitions into G2 or mitosis.
As shown in Figure  5B and Table S2 in Supplementary 
Material, analysis by IPA of all cell cycle genes affected by the 
inhibitors gave further insights into these potential mechanisms. 
IPA suggested that pathways related to DDR mechanisms (noted 
in bold in Figure 5B) were distinctly regulated by these inhibi-
tors. As pathways involved in the DDR are key in coordinating 
cell cycle progression with DNA repair and cell death/survival 
decisions, this analysis raised the possibility that arrest on G2/M 
by SPHK1-I treatment could be the result of unrepairable DNA 
damage or incomplete replication instead of regulation of cyclin 
expression.
FigUre 6 | Activation of the DNA damage response (DDR) cascade by inhibition of SPHK1. (a) Schematic representation of players in the DDR cascade. (B–D) 
Western blots analysis of HMC-1.2 lysates after treatment with SPHK1-I (10 µM), SPHK2-I (50 µM), or vehicle (0.1% DMSO) for 24, 48, or 72 h, showing changes in 
the activation/levels of various effectors in the DDR. (c) CHK2-dependent effectors of the DDR involved in the apoptotic pathway as illustrated in panel (a).  
(D) CHK2-dependent DDR effectors involved in cell cycle arrest as illustrated in panel (a). (e) Western blot analysis showing the phosphorylation state or expression 
levels of the indicated DDR effectors after the treatment of LAD2, HMC-1.1, and HMC-1.2 cells with 10 µM SPHK1-I or vehicle for 24 and 48 h. All blots are from a 
representative experiment of at least three separate experiments. Each membrane was probed with β-actin to demonstrate equal loading and these blots are shown 
in Figures S3A and S6 in Supplementary Material.
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inhibition of sPhK1 causes chK2-
Mediated DDr cascades leading  
to cell Death in hMc-1.2 cells
We next investigated whether the DDR-related pathways were 
indeed affected by inhibition of SPHK1 in HMC-1.2 cells and 
which of the possible DDR cascades were involved. DNA damage 
is sensed by the PI3K-like kinases ataxia telangiectasia and Rad3-
related protein (ATR) and ataxia telangiectasia mutated (ATM). 
ATR and ATM phosphorylate CHK1 and CHK2, respectively, 
which coordinate signaling cascades leading to cell cycle arrest 
and DNA repair or induce cell death or senescence if the damage 
cannot be repaired (51–53) (Figure  6A). While no significant 
effect on CHK1 or CHK2 phosphorylation was observed in 
cells treated with SPHK2-I, treatment with SPHK1-I markedly 
increased the phosphorylation of CHK2 in Thr68 (Figure  6B; 
Figure S3 in Supplementary Material), a site phosphorylated by 
ATM, suggesting an activation of ATM in response to double-
stranded breaks or telomere damage (54, 55). Consistent with 
this conclusion, HMC-1.2 cells treated with SPHK1-I showed 
increased phosphorylation of H2AX at Ser139 an early marker of 
double-stranded breaks. By contrast, SPHK1-I did not affect the 
phosphorylation in Ser345 of CHK1 but reduced CHK1 expres-
sion, indicating a unique activation of the DDR in HMC-1.2 cells, 
with CHK2 activation but simultaneous depletion of CHK-1, 
which could have catastrophic effects on cells.
Phosphorylation of CHK2 may activate an array of effectors 
in the DDR that orchestrates the cell outcome (Figure  6A). 
Phosphorylation of p53 at Ser20, a residue that is a substrate 
for CHK2, was substantially increased by SPHK1-I. Increased 
p53 phosphorylation, as expected, resulted in the stabilization 
of p53 and thus increased levels compared with untreated cells 
(Figure 6C; Figure S3 in Supplementary Material). Downstream 
of p53 and consistently with its tumor suppressor activity, the 
levels of its transcriptional targets, the pro-apoptotic BAX, and 
the anti-apoptotic BCL2 were upregulated and downregulated, 
respectively. As a consequence, the executioner CASP3 was 
cleaved and activated. Cleaved CASP2 was also increased after 
treatment with SPHK1-I but not with SPHK2-I (Figure 6C; Figure 
S3 in Supplementary Material). Although CASP2 cleavage may 
occur via CASP3, CASP2 activation by SPHK1-I is also in agree-
ment with the observed reduction in CHK1 levels, an effect that 
has been reported to limit DNA repair and induce apoptosis via 
CASP2 (56–58) (Figure 6A). The results suggest that inhibition of 
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SPHK1 causes cell death in HMC-1.2 by selectively activating the 
CHK2/p53/CASP3 pathway and causing CHK1 depletion with 
consequent CASP2 activation.
Activation of the DDR may also lead to arrest of cells in vari-
ous stages of the cell cycle. Consistent with the observed cell cycle 
arrest in G2/M, SPHK1-I but not SPHK2-I caused a depletion 
of the dual-specificity phosphatase CDC25c (Figure 6D; Figure 
S3 in Supplementary Material) which removes the inhibitory 
phosphate residues from CDK1 and allows the cell cycle to 
proceed. This effect on CDC25c is likely to be a consequence of 
SPHK-1 induced activation of CHK2 since CHK2 was reported to 
mediate either ubiquitination/degradation or phosphorylation/
inactivation of CDC25c (53, 55). In addition, CDK1 expression 
levels were also markedly reduced by SPHK1-I treatment. The 
depletion of CDK1 ensures no further progression into mitosis. 
Furthermore, the expression of growth arrest and DNA damage-
inducible (GADD45α), another transcriptional target of p53 that 
mediate cell cycle arrest (59), were increased in HMC-1.2 cells 
treated with either SPHK1-I or SPHK2-I (Figure 6D; Figure S3 in 
Supplementary Material). Overall, the data showing GADD45α 
upregulation supports the view that both inhibitors slow down 
entry into the cell cycle (G1/S) but an additional and more 
prominent and catastrophic consequence of SPHK1 inhibition in 
HMC-1.2 cells is the activation of the DDR, with CHK2-mediated 
G2/M arrest via CDC25c and CDK1 depletion as well as apoptotic 
cell death via CHK2/p53 and CHK1/CASP2 pathways.
activation of chK2 by sPhK1-i is More 
Prominent in cells With D816V-KiT
We then tested whether the activation of this pathway by 
SPHK1-I correlated with its effects on the cell cycle and apoptosis 
in the different cell lines. Concomitantly with the effect on G2/M 
arrest and apoptosis, the effect of SPHK1-I treatment on CHK2 
phosphorylation and CASP3 activation was more pronounced in 
HMC-1.2 than in HMC-1.1 and in LAD2 cells (Figure 6E; Figure 
S4 in Supplementary Material), which lack D816V-KIT. Similarly, 
treatment of murine P815 cells (harboring D816V-KIT) with 
SPHK1-I also induced Chk2 phosphorylation, p53 stabilization, 
and Casp3 activation, while this pathway was not observed in 
normal mouse BMMCs (Figure S5A in Supplementary Material). 
In addition, SPHK1-I induced a more pronounced CHK2 phos-
phorylation in HCT116 carrying D816V-KIT than the parental 
HCT116 cells (Figure S5B in Supplementary Material). Thus, 
these data implicate activation of the DDR by SPHK1-I as a 
mechanism involved in the increased susceptibility of cells with 
D816V-KIT to this inhibitor.
sPhK inhibitors reduce growth of Bone 
Marrow neoplastic Mcs From Patients 
and of ectopic Mc Tumors in Mice
To further assess the potential effectiveness of these inhibitors 
in preclinical models, we first treated bone marrow cells from 
four different patients with indolent and smoldering mastocyto-
sis (see Table S1 in Supplementary Material) with SPHK1-1 or 
SPHK2-I. After 5 days in culture, the number of bone marrow 
malignant CD25+ MCs was substantially reduced by treatment 
with SPHK1-I and SPHK2-I (Figure 7A). Similarly, these inhibi-
tors reduced by >50% the number of CD25+ MCs in 6-week-old 
CD34+-derived MC cultures from peripheral blood from one of 
the patients (Figure 7B). Whereas SPHK2-I was similarly effec-
tive in reducing MC numbers from normal donors (compare 
Figure  7B to Figure  1C), SPHK1-I significantly inhibited the 
growth of patient’s CD25+ MCs but not normal donor’s HuMCs 
(compare Figures 7B and 1C).
We next examined whether SPHK inhibition could also 
reduce the growth of D816V-KIT MCs in  vivo in a xenograft 
mouse model. HMC-1.2 cells inoculated subcutaneously into 
immunodeficient mice formed palpable ectopic tumors that 
grew steadily over the course of the experiment. Mice treated 
daily with SPHKI-1 (20 mg/kg) or SPHK2-I (40 mg/kg) after the 
tumors were palpable (50 mm3) showed a significant reduction 
in tumor volume over time compared with those in mice treated 
with vehicle (Figure 7C). The inhibition of growth by SPHK1-I 
and SPHK2-I of primary neoplastic MCs from patients and of 
D816V-KIT MCs in  vivo support the conclusion that SPHK 
inhibitors are appropriate candidates to consider for clinical 
applications in the treatment of mastocytosis.
DiscUssiOn
Advanced SM can result in aggressive neoplastic MC infiltrates 
in tissues and end-of-organ compromise, requiring cytoreduc-
tive therapy. Current treatments targeting oncogenic D816V-KIT 
have shown limited long-term improvement and thus additional 
therapeutic approaches are needed. In this study, we find that 
SPHK1 and SPHK2, the enzymes responsible for the generation 
of the lipid mediator S1P, are upregulated in neoplastic human 
MCs and critically regulate their proliferation/survival. We also 
demonstrate the effectiveness of inhibition of SPHK1 and SPHK2 
in reducing the numbers of malignant bone marrow MCs from 
patients with SM and in vivo in xenograft models. Of particular 
interest, inhibition of SPHK1 by SKI-178 prevented entry into 
mitosis and induced cell death most prominently in MCs with 
D816V-KIT. This involved the activation of CHK2 kinase con-
comitant with the depletion of CHK1, and downstream induction 
of the DDR leading to cell death. Overall, the data presented sug-
gest great potential for SPHK inhibitors as alternatives to tyrosine 
kinase inhibitors in the treatment of aggressive SM.
Sphingosine kinases, especially SPHK1, are well-recognized 
regulators of proliferation and survival, although their involve-
ment in these processes depends on the cell type. We find that 
neoplastic human MCs with oncogenic KIT mutations (includ-
ing HMC-1.2 and bone marrow CD25+ malignant MC from 
patients with SM) as well as other cells carrying D816V-KIT, are 
more vulnerable to inhibition of SPHK1 than normal MCs or 
other cell counterparts lacking this mutation. This suggests that 
SPHK1 may mediate critical oncogenic pathways of D816V-KIT 
and, together with findings that loss of SPHK1 reduces bioac-
tive mediator release by human MCs (28, 29), make SPHK1 
a more desirable target for therapeutic development than 
SPHK2 since it blocks both proliferation and function of MCs. 
Nonetheless, the SPHK2-I used in this study may also represent 
a drug of interest in the treatment of aggressive mastocytosis 
FigUre 7 | Inhibition of SPHK1 or SPHK2 reduces neoplastic mast cell (MC) number from bone marrows of patients with systemic mastocytosis and reduces 
growth of D816V-KIT MCs in a xenograft mouse model. (a) 0.5 × 106 CD34+ cells from bone marrow aspirates from four independent donors with systemic 
mastocytosis (Table S1 in Supplementary Material) were cultured for 5 days in the presence of SPHK1-I (10 µM), SPHK2-I (50 µM), or vehicle (0.1% DMSO) in 
culture media. Total numbers of CD34−/CD25+/KIT+/FcεRI+ in each sample as determined by FACS analysis were calculated from the percentages of each gated 
population. Horizontal dotted lines represent the number of CD34−/CD25+/KIT+/FcεRI+ originally plated at day 0. This analysis at day 0 was not done for patients 3 
and 4 due to limited number of available cells in those marrow aspirates. (B) CD34+ progenitors from whole blood were cultured for 6 weeks and treated with the 
inhibitors or vehicle as in panel (a) and analyzed by flow cytometry. Data were calculated as in panel (a). (c) Mice were inoculated subcutaneously with 1 × 106 
HMC-1.2 cells and allowed for tumors to grow to 50 mm3 in volume. Mice were then injected daily (i.p.) with 20 mg/kg SPHK1-I, 40 mg/kg SPHK2-I, or vehicle 
(PEG400 + 5% DMSO) and tumor volume measured (n = 5/group). Shown on the right are images of three representative tumors excised from each group of mice.
11
Bandara et al. SPHKs and Neoplastic MC Growth
Frontiers in Immunology | www.frontiersin.org March 2018 | Volume 9 | Article 631
since it is already in clinical trials for other malignancies and 
as demonstrated here, is also quite effective in reducing the 
numbers of CD25+ MCs and other neoplastic MCs. The find-
ing that SPHK2-I also affects the growth of normal MCs may 
not detract from its use, since imatinib-induced depletion of 
normal MCs during imatinib therapy did not show adverse 
clinical manifestations (60).
An unexpected observation in this study was the differential 
effects of SPHK1 compared with SPHK2 inhibition despite their 
similar effects in reducing cellular S1P levels. SPHK1 inhibition 
resulted predominantly in G2/M arrest and an induction of 
apoptosis that could not be explained by increased ceramide 
levels, while SPHK2 inhibition accumulated cells in G0/G1, 
slowing entry into the cell cycle. The arrest in G0/G1 by blockage 
of SPHK2 is relatively consistent among cells (46, 61, 62) but 
reports suggest that blockage of SPHK1 activity may arrest cells 
in G2/M or G0/G1 depending on the cell type (14, 15, 63, 64). 
We found that both inhibitors similarly regulate the expression 
of cyclins in HMC-1.2, with a pattern consistent with a predicted 
arrest in G0/G1. A defining effect of SPHK1 suppression in 
neoplastic MCs, particularly those harboring D816V-KIT, was 
a deregulation of the DDR cascade which prevented entry into 
mitosis (G2/M arrest) of those cells that had passed the G0/G1 
checkpoint, leading to them to programmed cell death. We pro-
pose this mechanism may be common to certain types of cancer 
cells and may partially explain the diverse effects on the cell cycle 
by SPHK1 blockage.
The activation of the DDR by SPHK1-I in D816V-KIT MCs 
was initiated by double-stranded breaks and induction of CHK2 
activity. This effect has not been previously reported, but in other 
cancer cells, knockdown of SPHK1 and reduction in S1P levels 
sensitize them to DNA damage by ionizing radiation (IR) (65) or 
by doxorubicin (66). In D816V-KIT MCs, activation of CHK2 by 
SPHK1-I mediated a depletion of CDC25c, a phosphatase needed 
for the removal of an inhibitory residue in CDK1 before entry 
into mitosis, and a downregulation in CDK1, which is needed for 
the induction of mitosis when complexed with cyclin B. Activated 
CHK2 also phosphorylated and stabilized p53, which then 
increased BAX but reduced BCL2 levels, resulting in cleavage 
and activation of the executioner CASP3. In addition to CHK2 
activation, CHK1 was distinctly depleted by SPHK1-I treatment, 
an observation consistent with a compromise in DNA repair and 
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activation of CASP2. Inactivation or loss of CHK1 under robust 
genotoxic insults or IR damage drives a type of cell death that can 
bypass p53 deficiency. This has been the basis for recent treat-
ment strategies in refractory cancers that would combine DNA 
damage-promoting drugs with inhibitors of CHK1 (57, 67, 68). 
Our data pose the intriguing possibility that SPHK1 inhibition 
on its own can act in D816V-KIT MCs like such proposed com-
bination therapy (67) since it activates a CHK2-induced DDR 
while shutting down CHK1-induced repair, ensuring apoptosis 
of the transformed cells by p53-dependent and -independent 
mechanisms. These observations in turn suggest that synergistic 
treatments with anticancer drugs that cause DNA damage may 
prove even more effective.
The specific mechanism by which inhibition of SPHK1 
by SKI-178 causes DNA double-stranded breaks is, however, 
unclear. The possibility that the inhibitor directly causes DNA 
damage is unlikely because LAD2 cells were not sensitive to 
this inhibitor or exhibited H2AX phosphorylation. A similar 
cascade of CHK2 activation, CDC25c depletion, p53 and CASP3 
activation has been described after loss of telomere stability 
initiated by either reduced telomerase activity or alterations in 
the complexes that protect telomeres (55, 69–74). Since nuclear 
S1P generated by SPHKs stabilizes the catalytic subunit of tel-
omerase (human telomerase reverse transcriptase, hTERT) (75), 
an interesting possibility is that SPHK1 may become critical for 
the proliferation and viability of cells with oncogenic D816V-KIT 
by preventing double-stranded breaks at fragile sites, particularly 
telomeres, during oncogene-induced replication stress. SPHK1 
in these cells may support hTERT activity, which is increased in 
HMC-1.2 compared with normal human MCs (76), or promote 
repair mechanisms, which are upregulated in oncogenic cells. 
Nevertheless, further studies are needed to identify whether these 
or other mechanisms are involved.
In conclusion, this study determines that SPHK activities are 
important regulators for the proliferation of normal and neoplas-
tic MCs in vitro and in MCs of patients with mastocytosis ex vivo. 
Moreover, we show that inhibition of their activity reduces MC 
burden in a xenograft model of neoplastic MCs and identify 
SPHK1 as an efficacious target for oncogenic KIT signaling. 
SPHK1 inhibition triggers an apoptotic program that resembles 
DDR-mediated apoptosis resulting from loss of telomere stabil-
ity. Although more studies are necessary to evaluate the clinical 
potential of these inhibitors, our data show promise targeting 
SPHKs as an effective therapy, perhaps in combination with 
existing therapies, in the treatment of aggressive mastocytosis 
and other diseases involving D816V-KIT mutations.
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